Bryant-Li-Bhoj Neurodevelopmental Syndrome 1 (BRYLIB1): Comprehensive Research Report

1. Disease Information

Overview. Bryant-Li-Bhoj neurodevelopmental syndrome (BLBS/BRYLIB) is a rare, clinically variable neurodevelopmental (and, in a subset of adults, neurodegenerative) disorder first delineated in 2020 and caused by heterozygous germline variants in one of the two genes that encode replication-independent histone H3.3: H3-3A (formerly H3F3A) and H3-3B (formerly H3F3B). Variants in H3-3A define Bryant-Li-Bhoj neurodevelopmental syndrome 1 (BRYLIB1); variants in H3-3B define the molecularly and clinically similar BRYLIB2. The condition was named for the discovery team (Bryant, Li, Bhoj) in the founding report ("Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients," Science Advances, 2020). GeneReviews describes it as "characterized by developmental delay/intellectual disability... and nonspecific craniofacial abnormalities," with a highly variable, gene-dosage-sensitive presentation (GeneReviews, NBK595206, updated 2023) [https://www.ncbi.nlm.nih.gov/sites/books/NBK595206/].

Key identifiers: - OMIM (phenotype): #619720 — BRYANT-LI-BHOJ NEURODEVELOPMENTAL SYNDROME 1; BRYLIB1 (https://www.omim.org/entry/619720) - OMIM (gene): 601128 — H3 HISTONE, FAMILY 3A; H3F3A / H3-3A (https://omim.org/entry/601128) - Related disorder: OMIM #619721 — BRYLIB2 (H3-3B, gene 601058), the sister condition - MONDO: MONDO:0030606 (Bryant-Li-Bhoj neurodevelopmental syndrome 1), confirmed via ClinGen curation (https://search.clinicalgenome.org/kb/conditions/MONDO:0030606) - HGNC: H3-3A, HGNC:4764 - ClinGen gene-disease validity: Definitive (Syndromic Disorders GCEP, classification date 2024-03-19) - Orphanet: no distinct ORPHA number could be confirmed in this search (the entity is very recently named, 2022 OMIM addition; it may still be tracked in Orphanet under a broader "H3.3-related chromatinopathy" heading rather than a dedicated ORPHA code) - Synonyms: BRYLIB1; Bryant-Li-Bhoj syndrome (BLBS); H3.3-related neurodevelopmental disorder; H3-3A-related neurodevelopmental disorder; (historically, before nosologic separation from cancer-associated somatic H3.3 mutations) "H3F3A germline neurodevelopmental disorder"

Data provenance: Nearly all current knowledge derives from aggregated case-series/cohort resources (GeneReviews, the 2020 founding cohort of 46 patients, and a 2024 expansion to 96 total individuals) built from clinician-submitted, ClinVar-deposited, and literature case reports — not from a population-level EHR resource. This is disease-level/aggregated-cohort evidence, not raw individual-patient EHR data.

2. Etiology

Primary cause — genetic, autosomal dominant, de novo. BRYLIB1 is caused by heterozygous, essentially always de novo pathogenic variants in H3-3A. GeneReviews states plainly: "BRYLIB is an autosomal dominant disorder typically caused by a de novo pathogenic variant." Parental testing in reported cohorts has confirmed de novo origin in essentially all cases; the 2024 expansion cohort reported the field's first exception — a maternally inherited H3-3B variant (p.Asn108Ser) in a mildly affected mother and child, establishing that (at least for H3-3B) transmission from a mosaic or mildly affected parent is possible (Layo-Carris et al., Eur J Hum Genet 2024;32(8):928–937, PMID: 38678163).

Genetic risk factors. The disease-causing variant itself is the risk factor; there is no described susceptibility-locus or polygenic contribution. gnomAD constraint metrics show H3-3A and H3-3B are highly intolerant to variation (missense z-scores of 3.16 and 2.88, respectively), consistent with the observation that even single heterozygous substitutions are clinically impactful (Layo-Carris et al. 2024).

Modifier factors / phenotype drivers. The affected gene (H3-3A vs H3-3B), the protein domain hit (N-terminal tail, aa 1–43, vs. histone-fold core, aa 44–135), and sex all statistically associate with different symptom sub-profiles (see Genotype-Phenotype Correlations, section 4/6), but the authors explicitly caution that "the current stratification by sex, affected gene, or affected protein domain does not account for all phenotypic variation observed," implicating unidentified modifiers — possibly epigenetic or gene-environment interaction effects, since "histone biology sits at the genetics-epigenetics interface" (Layo-Carris et al. 2024).

Environmental/lifestyle risk factors. None identified; this is a Mendelian single-gene disorder with no established environmental etiologic contribution.

Protective factors. None reported.

Somatic vs. germline distinction (important etiologic contrast). Identical or adjacent missense substitutions occurring somatically in H3-3A (notably p.Gly34Arg/Val and p.Lys27Met) are well-known oncogenic drivers of pediatric diffuse midline glioma and giant cell tumor of bone. In BRYLIB1/2, the same or neighboring residues are altered germline, and critically, no oncologic complications have been reported in the BLBS germline cohort to date, despite two individuals carrying germline p.Gly34Arg/Val substitutions identical to oncogenic somatic hotspots (Bryant et al. 2020; Layo-Carris et al. 2024). This is mechanistically informative: PTM/chromatin dysregulation in the germline, congenital setting differs qualitatively from the global histone-code disruption caused by somatic "oncohistone" mutations.

3. Phenotypes

Frequencies below combine GeneReviews (n=57), the founding 2020 cohort (n=46), and the 2024 expanded cohort of 96 total individuals (58 previously reported + 38 new; Layo-Carris et al. 2024, PMID 38678163), which is the most complete phenotype table available.

Onset/progression/severity. Developmental delay is evident from infancy/early childhood; the reported age range at evaluation spans 10 weeks to 39 years, so the natural history now extends well into adulthood. Notably, this is one of the few histone-related NDDs with a documented adult-onset neurodegenerative component: "all reported adults have had a new subacute onset of motor issues in the third decade of life that generally remains stable after onset," manifesting principally as camptocormia (progressive bent-spine posture) — the feature that anchors the "neurodegenerative" half of the syndrome's Science Advances title. Hypotonia can resolve or evolve into a mixed axial-hypotonia/peripheral-hypertonia pattern with age; this mixed pattern was found to occur exclusively in individuals with variants in the histone core domain (see Section 6).

Quality of life impact. Not separately quantified with EQ-5D/SF-36 instruments in the literature reviewed; qualitatively, impact is substantial given near-universal moderate-to-severe intellectual disability, motor delay, and (in a subset) adult-onset progressive motor decline, feeding difficulties, and seizures requiring ongoing neurological management.

4. Genetic/Molecular Information

Causal gene: H3-3A (HGNC:4764; OMIM 601128), chromosome 1q42.12, encoding replication-independent histone H3.3. (BRYLIB2 is caused by H3-3B, OMIM 601058, chromosome 17q25.1 — the two genes encode an essentially identical H3.3 protein and produce clinically overlapping disease.)

Variant spectrum: - BRYLIB1 (H3-3A): overwhelmingly de novo heterozygous missense variants, identified in the founding cohort in 33 unrelated patients, "found by whole-exome or genome sequencing, occurred throughout the gene" (OMIM #619720, citing Bryant et al. 2020). - BRYLIB2 (H3-3B): greater variant diversity, including a synonymous variant acting as a cryptic stop-gain in a non-canonical transcript (p.Val117Val), a stop-loss variant (p.Cys136ext9, a 2-nt deletion ablating the stop codon), and the one known inherited variant (p.Asn108Ser). - Across the combined 96-individual cohort: 70 unique causative variants*, distributed throughout the H3.3 protein rather than clustered at one or two hotspots — in contrast to the sharply localized cancer "oncohistone" hotspots (K27, G34, K36). - Representative variants: H3-3A p.Thr45Ile (T45I) — the most recurrently reported variant, now used to generate a mouse model (see Section 15); H3-3A p.Thr46Ile; H3-3B p.Leu48Arg (L48R) — used to generate an iPSC model; H3-3A/B p.Gln125Arg (shared, 8 individuals, discordant phenotypes); germline p.Gly34Arg/Val in H3-3B (mirrors the somatic oncohistone hotspot but with no oncologic phenotype). - ClinVar entry example: NM_002107.7(H3-3A):c.137C>T (p.Thr46Ile), classified pathogenic/likely pathogenic for BRYLIB1 (https://www.ncbi.nlm.nih.gov/clinvar/RCV001823766/).

Variant classification (ACMG/AMP): Pathogenic/likely pathogenic missense (and the rarer truncating/stop-loss/cryptic-splice) variants; interpreted per standard ACMG/AMP criteria plus gene-specific de novo and functional evidence used by the ClinGen Syndromic Disorders GCEP, which rated the H3-3A–BRYLIB1 relationship Definitive.

Allele frequency: Not present (or present only as ultra-rare singleton entries) in gnomAD/population databases, consistent with strong purifying selection (missense z-scores >2.8 for both genes) and complete penetrance of de novo disease alleles.

Somatic vs. germline: BRYLIB1/2 are strictly germline disorders; the same H3-3A/H3-3B residues altered somatically (K27M, G34R/V, K36M) instead cause pediatric high-grade/diffuse midline glioma and giant cell tumor of bone — an important differential/molecular contrast, not a subtype of BRYLIB1.

Functional consequences. Molecular modeling of the founding cohort's 37 variants "demonstrated clear disruptions in interactions with DNA, other histones, and histone chaperone proteins" (Bryant et al. 2020). Patient-derived histone post-translational modification (PTM) profiling showed "notably aberrant local PTM patterns distinct from the somatic lysine mutations that cause global PTM dysregulation" — i.e., germline variants perturb the histone code locally/regionally rather than globally. RNA-seq on patient cells showed "up-regulated gene expression related to mitosis and cell division, with increased proliferative capacity." A specific structural mechanism identified for one recurrent variant (H3-3A p.Arg129His) was "significantly stronger interaction with DAXX," the H3.3-specific histone chaperone, implicating disrupted, chaperone-mediated H3.3 deposition (Tsuchiya et al./de novo-variant cohort, PMC8651650). For H3-3B p.Leu48Arg, iPSC modeling indicates the variant "increases H3-3B expression, resulting in the hyper-deposition of H3.3 into the nucleosome" (see Section 6).

Modifier genes: None formally established; phenotype correlates statistically with affected gene and protein domain (tail vs. core) rather than with a distinct modifier locus (see Section 6).

Epigenetic information: This is fundamentally an epigenetic-machinery disorder — the causal protein is a core chromatin component. Aberrant local histone PTM deposition and altered chromatin accessibility (documented directly by ATAC-seq/multi-omic profiling in iPSC-derived neural models) are central to pathogenesis rather than secondary.

Chromosomal abnormalities: Not a copy-number/structural disorder; disease is driven by single-nucleotide/small-indel variants in H3-3A. Gene-targeted deletion/duplication analysis detection rate is not established (no cases reported to date attributable to CNV).

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors have been identified or proposed for BRYLIB1 beyond the theoretical, unproven suggestion in the 2024 expanded-cohort paper that "gene-environment interactions" might help explain residual phenotypic variability not accounted for by gene/domain/sex stratification — this is explicitly speculative rather than evidence-based (Layo-Carris et al. 2024).

6. Mechanism / Pathophysiology

Molecular substrate. H3.3 is a replication-independent histone variant (as opposed to the replication-dependent canonical H3.1/H3.2) that is deposited onto DNA by the DAXX/ATRX and HIRA histone chaperone complexes, especially at transcriptionally active regions, telomeres, and pericentric heterochromatin. Two molecules of each core histone (H2A, H2B, H3, H4) assemble into the octamer around which ~146 bp of DNA wraps to form the nucleosome; H3.3 is essential for chromatin compaction, early embryonic development, and cell-lineage commitment. Suggested GO terms: GO:0000786 (nucleosome), GO:0031507 (heterochromatin formation), GO:0006335 (DNA replication-independent nucleosome assembly), GO:0016575 (histone deacetylation)/relevant PTM GO terms, GO:0006338 (chromatin remodeling).

Causal chain (as currently understood): 1. Trigger (molecular/upstream): De novo missense (or rare truncating/inherited) variant in H3-3A alters the H3.3 protein at a residue involved in DNA contact, chaperone binding (e.g., DAXX interaction, strengthened for p.R129H), or inter-histone (H3-H4/H2A-H2B) contacts within the nucleosome. 2. Molecular consequence: Disrupted or altered-affinity interactions with DNA, chaperones, and neighboring histones; in some variants (e.g., L48R) increased H3-3B expression and hyper-deposition of H3.3 into nucleosomes rather than simple loss-of-function. 3. Chromatin-level consequence: Aberrant, locally restricted (not globally dysregulated, unlike somatic oncohistones) deposition of histone PTMs, producing a disrupted local "histone code." 4. Gene-regulatory consequence: Genome-wide, cell-type-specific dysregulated gene expression and altered chromatin accessibility — documented in iPSC-derived neural progenitor cells, forebrain neurons, and organoids as changes affecting genes governing "neuronal fate, adhesion, neurotransmission, and excitatory/inhibitory balance" (Journal of Translational Medicine 2026 iPSC paper, PMC11382994). Patient fibroblasts additionally show up-regulated mitosis/cell-division transcriptional programs and increased proliferative capacity (Bryant et al. 2020). 5. Cellular consequence: Altered proportions of radial glia versus mature neuronal populations in organoids; decreased spontaneous electrical activity in L48R-mutant forebrain-organoid neurons by patch-clamp electrophysiology, indicating impaired neuronal maturation/functional network formation. 6. Organismal/clinical consequence: Global developmental delay/intellectual disability, dysmorphic craniofacial features, hypotonia/hypertonia, seizures, structural brain anomalies (hypomyelination, corpus callosum dysgenesis, small posterior fossa), and — in the neurodegenerative arm of the phenotype — adult-onset progressive camptocormia/motor decline, presumably reflecting cumulative disruption of H3.3's dominant role in post-mitotic neuronal chromatin maintenance over decades (H3.3 becomes >93% of total neuronal H3 in mature neurons, versus ~31% of the H3 pool during early neurodevelopment).

Upstream vs. downstream framing: Upstream = the germline histone variant itself (a cell-autonomous, constitutive lesion present from the zygote onward, not one triggered by an external event). Midstream = chromatin/PTM/accessibility dysregulation. Downstream = neurodevelopmental (congenital) phenotypes plus a distinct, temporally separate downstream neurodegenerative phenotype (adult camptocormia) that appears to require decades of cumulative dysfunction in postmitotic neurons — consistent with the biological observation that H3.3 dependence increases sharply as neurons mature and exit the cell cycle.

Cell types/processes implicated: Neural progenitor cells, radial glia, cortical/forebrain excitatory neurons (maturation and electrophysiological function), cranial neural crest cells (craniofacial dysmorphism, per zebrafish data), and — per RNA-seq of patient fibroblasts — mitotically active non-neural cells showing increased proliferation. Suggested CL terms: CL:0000047 (neural progenitor cell/stem cell), CL:0002608 (radial glial cell), CL:0000540 (neuron)/CL:0000598 (pyramidal neuron), CL:0002500 (cranial neural crest cell).

Genotype-phenotype correlation (protein-domain level, from the 96-individual 2024 cohort): - N-terminal tail variants (aa 1–43): associated with undergrowth (44%), abnormal neuroimaging (63%), hypotonia (73%), dermal features (64%), delayed sitting (59%). - Histone-fold core variants (aa 44–135): associated with the mixed axial-hypotonia/peripheral-hypertonia pattern (exclusively seen with core variants), higher rates of overweight (25% vs 7%) and cardiac anomalies (17% vs 7%), and more often normal height. - Gene-level: H3-3A variants trend toward more craniofacial dysmorphism (95% vs 86%) and more delayed walking (85% vs 65%); H3-3B variants trend toward higher seizure prevalence (59% vs 45%), more macrocephaly (53% vs 43%), and more genital anomalies (28% vs 17%). - Sex: males show more delayed walking and speech delay; females show more oculomotor dysfunction; seizure prevalence and overall developmental-delay severity do not differ significantly by sex. - Critically, identical variants produce discordant phenotypes (e.g., four individuals with H3-3A p.Thr45Ile, and eight individuals sharing p.Gln125Arg across both genes, show substantial phenotypic variability), so genotype-phenotype rules are statistical trends, not deterministic.

Advanced/omics technologies used to date: multi-omic (transcriptomic + chromatin-accessibility/ATAC-like) profiling of iPSC-derived 2D neural progenitor cells and forebrain neurons; single-cell/organoid-level immunofluorescence characterization of 3D dorsal forebrain organoids; patch-clamp single-cell electrophysiology. No published single-cell RNA-seq atlas, spatial transcriptomics, or CRISPR functional-genomics screen specific to BLBS was identified in this search.

7. Anatomical Structures Affected

Organ level: Primary — central nervous system (brain: cortex, corpus callosum, posterior fossa/cerebellum, white matter); craniofacial skeleton (skull shape, craniosynostosis). Secondary — cardiovascular system (atrial septal defect and other congenital heart defects), musculoskeletal system (scoliosis, other skeletal anomalies, adult-onset camptocormia of the spine), genitourinary system (cryptorchidism, other genital anomalies), integumentary system (dermatologic features), auditory system (hearing loss), ocular system (strabismus, nystagmus, other oculomotor dysfunction), endocrine system (hypothyroidism reported in the sister Rahman-syndrome literature and surveilled for in BLBS management protocols).

Body systems involved: nervous, musculoskeletal, cardiovascular, ocular, auditory, endocrine, genitourinary, integumentary — a genuinely multisystem chromatinopathy centered on but not limited to neurodevelopment. Suggested UBERON terms: UBERON:0000955 (brain), UBERON:0002336 (corpus callosum), UBERON:0002037 (cerebellum), UBERON:0002298 (brainstem/posterior fossa structures), UBERON:0003128 (skull).

Tissue/cell level: cerebral cortical neurons and their progenitors (radial glia); cranial neural crest-derived craniofacial mesenchyme; cardiac septal tissue; ocular extraocular muscle/oculomotor control circuitry.

Subcellular level: the nucleus/chromatin is the primary subcellular compartment affected — the nucleosome itself (GO Cellular Component: GO:0000786 nucleosome; GO:0000785 chromatin; GO:0005694 chromosome) is the direct molecular substrate of disease.

Localization/lateralization: No lateralization pattern reported; craniofacial and brain anomalies are typically bilateral/midline (e.g., corpus callosum, posterior fossa). Camptocormia is axial/midline (spine).

8. Temporal Development

Onset: Congenital/early childhood for the neurodevelopmental component (developmental delay evident in infancy); distinctly adult-onset (third decade) for the neurodegenerative motor component (camptocormia).

Progression: Two temporally distinct phases are now recognized — (1) a static-to-improving neurodevelopmental phase in childhood (hypotonia can resolve with age in some individuals), followed by (2) a subacute-onset, then stabilizing neurodegenerative motor phase beginning in early adulthood, universal among reported adults, that "generally remains stable after onset" rather than being relentlessly progressive. Seizures, when present, begin in childhood with variable, sometimes treatment-refractory, course.

Patterns: Developmental regression is reported in a minority of individuals, ranging mild to severe; no spontaneous full remission is described. No defined "critical period" for intervention has been established in the literature, though early developmental intervention (birth–age 3) is uniformly recommended in management guidance.

9. Inheritance and Population

Epidemiology: Ultra-rare; 96 individuals reported in the peer-reviewed literature as of the 2024 expanded cohort (58 previously known + 38 new), combined across BRYLIB1 (H3-3A, 65 individuals) and BRYLIB2 (H3-3B, 31 individuals). No population-based prevalence or incidence estimate (per 100,000) has been established; the condition is almost certainly ascertainment-limited (identified via exome/genome sequencing for undiagnosed neurodevelopmental disorders) rather than reflecting a stable epidemiologic denominator.

Inheritance pattern: Autosomal dominant, essentially always de novo; one confirmed maternally-inherited H3-3B case is the sole reported exception to date (2024 cohort). GeneReviews recurrence-risk guidance: for parents of an isolated proband, recurrence risk to siblings is ~1% (accounting for possible parental germline mosaicism) if parental testing is negative; risk to offspring of an affected individual is not yet established because few affected individuals have reached reproductive age.

Penetrance: Reported cases are essentially fully penetrant (all carriers described to date are symptomatic), though the founder mild inherited case (mother + child, p.Asn108Ser) suggests a spectrum extending toward milder/possibly under-ascertained presentations.

Expressivity: Markedly variable, even among carriers of the identical variant (documented explicitly for p.Thr45Ile and p.Gln125Arg) — this is one of the most striking features of the disorder and is explicitly flagged by the authors as only partially explained by gene, domain, or sex.

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Formally invoked as the explanation for the ~1% empiric sibling recurrence risk quoted by GeneReviews, though not directly demonstrated in a specific reported family to date in this search.

Founder effects / consanguinity: None reported; disease arises from de novo mutation, not from population-specific founder alleles or recessive consanguinity-driven inheritance.

Population demographics: No described ethnic, geographic, or ancestry-specific enrichment; cohorts to date are drawn from international, largely clinical-exome-sequencing-ascertained populations (US, European, and at least one Chinese cohort reported separately — see PMC ResearchGate "Bryant-Li-Bhoj neurodevelopmental syndrome: a case report in China and literature review"). Sex ratio: no marked male:female skew reported, though some phenotype features differ by sex in frequency (Section 6).

10. Diagnostics

Diagnostic criteria (GeneReviews): "The phenotypic features associated with Bryant-Li-Bhoj neurodevelopmental syndrome are not sufficient to diagnose this condition clinically." Diagnosis requires suggestive clinical findings plus identification of a heterozygous pathogenic/likely-pathogenic variant in H3-3A or H3-3B by molecular genetic testing.

Testing approach/order: 1. Chromosomal microarray analysis (initial broad screen, primarily to exclude a CNV-based alternative diagnosis) 2. Intellectual disability multigene panel including H3-3A/H3-3B 3. Exome or genome sequencing (most productive; used to identify the great majority of reported cases) 4. Single-gene sequential testing is explicitly "rarely useful and typically NOT recommended," given the phenotype's non-specificity.

Detection rate: Sequence analysis has detected essentially all reported pathogenic variants (39/39 H3-3A cases and 18/18 H3-3B cases in the cohort GeneReviews cites); detection rate for gene-targeted deletion/duplication (CNV) analysis is unknown/unestablished, since no CNV-mediated cases have been reported.

Imaging: Brain MRI is the key structural imaging modality — findings include small posterior fossa, corpus callosum hypoplasia/dysgenesis, delayed/hypomyelination, cortical dysplasia in a subset, and (in some individuals) leukoencephalopathy-pattern white-matter change.

Differential diagnosis: Because the phenotype (developmental delay + nonspecific dysmorphism + variable hypotonia/seizures) overlaps broadly with hundreds of other Mendelian intellectual-disability disorders, GeneReviews directs clinicians to the OMIM autosomal dominant, autosomal recessive, and X-linked intellectual developmental disorder phenotypic series for full differential consideration. Notably, close molecular differentials include the H1.4-linker-histone disorder Rahman syndrome (HIST1H1E/H1-4) — a distinct, separately named chromatinopathy causing overlapping intellectual disability, overgrowth, and dysmorphic facies, but mechanistically and molecularly separate (linker histone H1 vs. core nucleosomal histone H3.3) and must not be conflated with BRYLIB1/2 despite superficial resemblance and shared "histone-disorder" framing in review literature.

Genetic testing modalities: Standard clinical exome/genome sequencing is the primary and most productive tool; chromosomal microarray, karyotyping, FISH, and mitochondrial DNA testing are not primary diagnostic tools for this specific condition (used only to exclude alternative etiologies). No repeat-expansion or specialized epigenomic clinical test is part of the standard diagnostic pathway at this time, although research-grade histone PTM profiling and chromatin-accessibility assays have been used investigationally (see Section 6).

Screening: No newborn-screening, population carrier-screening, or cascade-screening program exists (as expected for an ultra-rare, almost-always de novo disorder); prenatal/preimplantation genetic testing is available once a familial pathogenic variant is identified.

11. Outcome/Prognosis

Survival/mortality: "It is unknown whether life span in BRYLIB is abnormal" (GeneReviews); several adults with the condition have now been reported, and life span does not appear to be markedly shortened by the condition itself based on current (still limited) natural-history data.

Morbidity/function: Chronic disability driven by moderate-to-severe intellectual disability, motor delay, and (in adulthood) progressive camptocormia; no tumors have been reported in individuals with germline H3.3 variants (an important reassurance point distinguishing this from the somatic oncohistone literature).

Disease course: Predominantly non-regressive/stable neurodevelopmental phenotype through childhood for most individuals, with a distinct adult-onset subacute motor decline (camptocormia) that then plateaus; a minority show frank developmental regression of variable severity.

Prognostic factors: No formal prognostic biomarker or scoring system has been developed; affected gene/domain and (to a lesser extent) sex have only modest, non-deterministic predictive value for symptom profile as discussed above.

12. Treatment

No disease-modifying or curative treatment exists. Management is entirely multidisciplinary and supportive, per GeneReviews Table 4 ("Treatment of Manifestations," https://www.ncbi.nlm.nih.gov/books/NBK595206/table/brylib.T.bryantlibhoj_neurodevelopmental_1/):

• Developmental/educational support: Early intervention (age 0–3), developmental preschool/special education, individualized education plans, physical/occupational/speech therapy. NCIT: NCIT:C15302 (Physical Therapy), NCIT:C15747 (Supportive Care), NCIT:C49236 (Therapeutic Procedure).
• Seizure management: Standardized anti-seizure medication under an experienced neurologist; multiple agent options exist, some individuals show treatment-refractory seizures. NCIT: NCIT:C15986 (Pharmacotherapy) with an anticonvulsant therapeutic_agent.
• Feeding/nutrition: Feeding therapy; gastrostomy tube placement for persistent feeding dysfunction; ongoing nutritional monitoring. NCIT: NCIT:C15447 (Dietary Intervention).
• Spasticity management: Physical therapy, positioning devices, antispasticity medications.
• Craniosynostosis: Surgical correction when clinically indicated. NCIT: NCIT:C16186 (Orthopedic Surgical Procedure) or NCIT:C15329 (Surgical Procedure).
• Ophthalmology: Ongoing care for strabismus/visual impairment.
• Audiology: Hearing-loss surveillance and intervention.
• Cardiology: Evaluation/management of congenital heart defects.
• Urology: Consultation for cryptorchidism.
• Endocrinology: Management of hypothyroidism when present.

Surveillance protocol (GeneReviews): at each visit — growth parameters, nutrition/oral-intake safety, constipation screening, new seizure or gait-change assessment, developmental-progress monitoring, behavioral screening; annually/as indicated — ophthalmology exam, audiology exam, thyroid function testing; and (per the 2024 expanded-cohort recommendations) repeat neuroimaging to track the progressive/neurodegenerative component and ongoing genitourinary surveillance.

Experimental/precision-medicine pipeline (very early stage, no clinical trials yet identified): The two most important recent developments are disease models built specifically to enable future targeted-therapy development: - iPSC model (H3-3B p.Leu48Arg): 2D neural progenitor cells, 2D forebrain neurons, and 3D dorsal forebrain organoids, characterized by multi-omic profiling, immunofluorescence, and patch-clamp electrophysiology (Journal of Translational Medicine, Feb 2026; PMC11382994, PMID 39253491). The authors explicitly frame this model as "a crucial step towards preclinical development and testing of targeted therapies." - Mouse model (H3-3A p.Thr45Ile), 2026 preprint: the first in vivo preclinical model, recapitulating "perinatal growth restriction, delayed developmental milestones, and progressive motor and gait impairments," plus adult craniofacial differences, impaired nest building, social-context hyperactivity, and male-specific elevated aggression (bioRxiv, June 2026, https://www.biorxiv.org/content/10.64898/2026.06.16.732665v1). This model is positioned to enable in vivo therapeutic testing going forward.

No NCT-registered clinical trial for a targeted BLBS therapy was identified in this search as of August 2026; the field remains at the mechanistic/preclinical-model stage.

13. Prevention

No primary, secondary, or tertiary prevention strategy exists beyond standard reproductive genetic counseling once a familial pathogenic variant is known (prenatal diagnosis, preimplantation genetic testing) — appropriate given the condition's near-universal de novo origin. No vaccination, screening program, or prophylactic medication applies. Genetic counseling is the principal "preventive" intervention offered to families, focused on recurrence-risk estimation (~1%, germline-mosaicism-based) for future pregnancies.

14. Other Species / Natural Disease

No naturally occurring veterinary or wildlife disease caused by spontaneous H3-3A/H3-3B variants has been reported (this is not currently listed in OMIA). H3.3 itself is highly evolutionarily conserved; the gene has functional orthologs across vertebrates, and a companion in vitro/model-organism paper — "Histone 3.3-related chromatinopathy: missense variants throughout H3-3A and H3-3B cause a range of functional consequences across species" (PMID 36867246) — used yeast as a heterologous functional-testing platform for patient-derived missense variants, and a separate paper examined "trapping of yFACT at 3' ends of genes" using yeast versions of BLBS histone H3 mutants (PMC11544422), underscoring cross-species conservation of the affected chaperone/FACT-complex interactions even though yeast do not model the neurodevelopmental phenotype itself.

15. Model Organisms

• Zebrafish: Homozygous h3f3a-mutant (db1092 allele) zebrafish injected with dominant-negative H3f3a RNA show "complete loss of melanocytes and severe reductions of glia and xanthophores throughout cranial and trunk regions"; reduced nuclear H3.3 caused by aggregating dominant-mutant H3.3 produces defects in cranial neural crest cell differentiation, demonstrating tissue-specific sensitivity to H3.3 dosage during craniofacial/pigment-lineage development — directly relevant to the craniofacial dysmorphism seen in human BLBS.
• Mouse: (1) Conditional H3f3a/H3f3b double-knockout embryos (H3f3a^fl/−; H3f3b^fl/−; Sox2-Cre) show H3.3 depletion with embryos recovering at expected Mendelian ratios only up to E10.5, indicating an essential, dosage-sensitive developmental requirement. During normal mouse neurodevelopment, H3.3 constitutes ~31% of total H3 pool early on, rising to become the dominant H3 species (>93%) in mature adult neurons — mechanistically explaining why postmitotic neurons are disproportionately vulnerable to H3.3 dysfunction and offering a rationale for the adult-onset neurodegenerative (camptocormia) component of BLBS. (2) The 2026 knock-in H3.3-T45I mouse (bioRxiv, June 2026) is the first genotype-matched in vivo preclinical model, recapitulating perinatal growth restriction, developmental-milestone delay, progressive motor/gait impairment, adult craniofacial differences, impaired nest-building, social-context hyperactivity, and male-specific aggression — directly paralleling multiple domains of the human phenotype and positioned as the platform for future therapeutic testing.
• Human iPSC-derived models: 2D neural progenitor cells, 2D forebrain neurons, and 3D dorsal forebrain organoids carrying H3-3B p.Leu48Arg (Journal of Translational Medicine, 2026) recapitulate disrupted chromatin accessibility, dysregulated neuronal-fate/adhesion/neurotransmission gene expression, altered radial-glia-to-neuron proportions, and decreased spontaneous neuronal electrical activity by patch-clamp — the most disease-relevant human cellular model to date.
• Yeast: used as a rapid, high-throughput heterologous system to functionally characterize the range of consequences of BLBS missense variants "across species," and to probe effects on the FACT histone chaperone complex (yFACT trapping at gene 3′ ends).
• Model limitations: none of the current models (zebrafish, mouse, iPSC/organoid, yeast) yet captures the full adult neurodegenerative phenotype (camptocormia) in a validated, long-term aging cohort; the 2026 mouse model is the first designed explicitly to test this, but published long-term follow-up data were not available at the time of this search.

Summary of Key Ontology Term Suggestions

• Gene/Disease: HGNC:4764 (H3-3A); MONDO:0030606 (BRYLIB1); OMIM:619720
• HPO (selected): HP:0001263 (Global developmental delay), HP:0001249 (Intellectual disability), HP:0001252 (Hypotonia), HP:0001276 (Hypertonia), HP:0001250 (Seizure), HP:0002079 (Hypoplasia of corpus callosum), HP:0000252 (Microcephaly), HP:0000486 (Strabismus), HP:0001363 (Craniosynostosis), HP:0031808 (Camptocormia), HP:0002317 (Unsteady gait)
• GO: GO:0000786 (nucleosome), GO:0006335 (DNA replication-independent nucleosome assembly), GO:0031507 (heterochromatin formation), GO:0006338 (chromatin remodeling)
• CL: CL:0000047 (neural progenitor cell), CL:0002608 (radial glial cell), CL:0000540 (neuron), CL:0002500 (cranial neural crest cell)
• UBERON: UBERON:0000955 (brain), UBERON:0002336 (corpus callosum), UBERON:0002037 (cerebellum)
• NCIT (treatment): NCIT:C15986 (Pharmacotherapy), NCIT:C15302 (Physical Therapy), NCIT:C15447 (Dietary Intervention), NCIT:C16186 (Orthopedic Surgical Procedure), NCIT:C15747 (Supportive Care)

Sources

• GeneReviews: Bryant-Li-Bhoj Neurodevelopmental Syndrome (updated 2023)
• OMIM #619720 — BRYLIB1
• OMIM #619721 — BRYLIB2
• OMIM *601128 — H3F3A/H3-3A
• ClinGen curation, MONDO:0030606
• Bryant L, Li D, Cox SG, et al. "Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients." Science Advances 2020. https://www.science.org/doi/10.1126/sciadv.abc9207 / PMC7821880
• Layo-Carris DE, et al. "Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals." Eur J Hum Genet 2024;32(8):928–937. PMID: 38678163; correction
• "De novo variants in H3-3A and H3-3B are associated with neurodevelopmental delay, dysmorphic features, and structural brain abnormalities." npj Genomic Medicine 2021. PMC8651650
• "A novel iPSC model of Bryant-Li-Bhoj neurodevelopmental/neurodegenerative syndrome demonstrates the role of histone H3.3 in chromatin dynamics, neuronal differentiation, and maturation." J Transl Med 2026. PMID: 39253491; PMC11382994
• "A novel preclinical mouse model recapitulates progressive phenotypes of Bryant-Li-Bhoj Syndrome." bioRxiv, June 2026. https://www.biorxiv.org/content/10.64898/2026.06.16.732665v1
• "Histone 3.3-related chromatinopathy: missense variants throughout H3-3A and H3-3B cause a range of functional consequences across species." PMID: 36867246
• "Trapping of yFACT at 3′ ends of genes is not a universal characteristic of yeast versions of Bryant-Li-Bhoj syndrome histone H3 mutants." PMC11544422
• "Neonatal myoclonus in Bryant-Li-Bhoj syndrome associated with a novel H3F3A variant." Hum Genome Var 2024. https://www.nature.com/articles/s41439-024-00303-x
• ClinVar RCV001823766 (NM_002107.7(H3-3A):c.137C>T, p.Thr46Ile) — https://www.ncbi.nlm.nih.gov/clinvar/RCV001823766/
• Note on differential diagnosis: Rahman syndrome (HIST1H1E/H1-4) is a molecularly and clinically distinct linker-histone disorder that should not be conflated with BRYLIB1/2 despite overlapping "histone disorder" framing — see Zhao et al., Mol Genet Genomic Med 2022 and Indugula et al., Clin Case Rep 2022 for comparison.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.1126/sciadv.abc9207](https://www.science.org/doi/10.1126/sciadv.abc9207 (1 mention) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0025265 (1 mention) - the report calls it "72% (in detailed-MRI subgroup)"; HP calls it Stiff toe
• HP:0031808 (2 mentions) - the report calls it "Camptocormia"; HP calls it Decreased total basophil count
• CL:0002608 (2 mentions) - the report calls it "radial glial cell"; CL calls it hippocampal neuron
• CL:0002500 (2 mentions) - the report calls it "cranial neural crest cell"; CL calls it P enteroendocrine cell

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0016575 (obsolete histone deacetylation) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002079 (2 mentions) - the report calls it "Hypoplasia of the corpus callosum", "Hypoplasia of corpus callosum"; HP calls it Hypoplasia of the corpus callosum, and lists "Hypoplasia of corpus callosum" among its other names
• GO:0006335 (2 mentions) - the report calls it "DNA replication-independent nucleosome assembly"; GO calls it DNA replication-dependent chromatin assembly, and lists "DNA replication-dependent nucleosome assembly" among its other names
• CL:0000047 (2 mentions) - the report calls it "neural progenitor cell"; CL calls it neural stem cell

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0030606 - called "Bryant-Li-Bhoj neurodevelopmental syndrome 1", "BRYLIB1"
• HP:0002079 - called "Hypoplasia of the corpus callosum", "Hypoplasia of corpus callosum"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM.